Incannex Healthcare Past Earnings Performance
Past criteria checks 3/6
Incannex Healthcare's earnings have been declining at an average annual rate of -17.3%, while the Pharmaceuticals industry saw earnings declining at 0.8% annually. Revenues have been growing at an average rate of 8.5% per year. Incannex Healthcare's return on equity is 113.8%, and it has net margins of 3107.8%.
Key information
-17.3%
Earnings growth rate
-18.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 8.5% |
| Return on equity | 113.8% |
| Net Margin | 3,107.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Incannex Healthcare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | 21 | 10 | 3 |
| 30 Sep 23 | 1 | 5 | 8 | 4 |
| 30 Jun 23 | 1 | -13 | 6 | 6 |
| 31 Mar 23 | 1 | -13 | 6 | 6 |
| 31 Dec 22 | 1 | -48 | 7 | 4 |
| 30 Sep 22 | 1 | -28 | 5 | 4 |
| 30 Jun 22 | 1 | -10 | 5 | 4 |
| 31 Mar 22 | 1 | -10 | 5 | 4 |
| 31 Dec 21 | 1 | -9 | 4 | 4 |
| 30 Sep 21 | 1 | -9 | 5 | 4 |
| 30 Jun 21 | 1 | -9 | 5 | 4 |
| 31 Dec 20 | 1 | -4 | 2 | 3 |
| 30 Sep 20 | 1 | -3 | 2 | 2 |
| 30 Jun 20 | 0 | -3 | 1 | 1 |
| 31 Dec 19 | 0 | -1 | 0 | 1 |
| 30 Sep 19 | 0 | -1 | 0 | 1 |
| 30 Jun 19 | 0 | -1 | 0 | 1 |
| 31 Mar 19 | 1 | -2 | 2 | 0 |
| 31 Dec 18 | 1 | -2 | 2 | 0 |
| 30 Sep 18 | 1 | -2 | 3 | 0 |
| 30 Jun 18 | 1 | -2 | 3 | 0 |
| 31 Mar 18 | 1 | -2 | 2 | 0 |
| 31 Dec 17 | 0 | -2 | 2 | 0 |
| 30 Sep 17 | 0 | -9 | 2 | 0 |
| 30 Jun 17 | 0 | -16 | 2 | 0 |
| 31 Mar 17 | 0 | -15 | 1 | 0 |
| 31 Dec 16 | 0 | -14 | 1 | 0 |
| 30 Sep 16 | 0 | -8 | 1 | 0 |
| 30 Jun 16 | 0 | -1 | 1 | 0 |
Quality Earnings: IXHL has a high level of non-cash earnings.
Growing Profit Margin: IXHL became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IXHL has become profitable over the past 5 years, growing earnings by -17.3% per year.
Accelerating Growth: IXHL has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: IXHL has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.7%).
Return on Equity
High ROE: IXHL's Return on Equity (113.8%) is considered outstanding.